Brought to you by 
Glenmark gets rights to sell generic form of Nycomed's Cutivate
06 Jun 2011
Executive Summary
Nycomed US Inc. (a division of Nycomed International Management GMBH) has entered into a royalty-bearing license agreement with Glenmark Pharmaceuticals Ltd.'s Glenmark Generics Ltd. to settle outstanding litigation. Nycomed had alleged that Glenmark’s ANDA for fluticasone 0.05% lotion infringed upon Nycomed's Cutivate for atopic dermatitis. Glenmark now has the right to sell its fluticasone lotion in March 2012; the company believes it will have 180 days of exclusivity since it will be the first generic on the market. Nycomed’s Cutivate had 2010 US sales of $48mm.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Glenmark gets rights to sell generic form of Nycomed's Cutivate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice